tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

AbbVie’s Rinvoq Study in Japan: A Closer Look at Ulcerative Colitis Treatment

AbbVie’s Rinvoq Study in Japan: A Closer Look at Ulcerative Colitis Treatment

Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.

Elevate Your Investing Strategy:

AbbVie is conducting a prospective observational study titled ‘A Prospective Observational Study for Evaluation of Safety and Effectiveness of Rinvoq in Moderately to Severely Active Ulcerative Colitis; a Japanese Post-Marketing Study.’ The study aims to evaluate the safety and effectiveness of Rinvoq in treating adult participants with moderate to severe ulcerative colitis (UC) in Japan, assessing changes in disease activity and adverse events.

The intervention being tested is Rinvoq, a drug approved for the treatment of UC. Participants will receive upadacitinib, the active ingredient in Rinvoq, as prescribed by their physicians according to routine clinical practice and local label guidelines.

This observational study follows a cohort model with a prospective time perspective. It involves approximately 300 adult participants in Japan, who will be monitored for up to 60 weeks during regular hospital or clinic visits.

The study began on December 19, 2022, with an actual start date. The primary completion and estimated completion dates are not specified, but the last update was submitted on July 15, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates.

This update could influence AbbVie’s stock performance positively by reinforcing investor confidence in Rinvoq’s market potential for UC treatment. It also positions AbbVie competitively within the pharmaceutical industry, particularly against other companies developing similar treatments.

The study is ongoing, with further details available on the ClinicalTrials portal.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1